
Sign up to save your podcasts
Or


Dr. Monty Pal shares highlights from Day 2 of the 2026 ASCO Annual Meeting, including a practice-changing trial in renal cell carcinoma, advances in ER-positive, HER2-negative early breast cancer, and the use of olanzapine as an effective steroid-sparing alternative for chemo-induced nausea and vomiting in pediatric cancer.
LINK TO FULL TRANSCRIPT
By American Society of Clinical Oncology (ASCO)4.6
5656 ratings
Dr. Monty Pal shares highlights from Day 2 of the 2026 ASCO Annual Meeting, including a practice-changing trial in renal cell carcinoma, advances in ER-positive, HER2-negative early breast cancer, and the use of olanzapine as an effective steroid-sparing alternative for chemo-induced nausea and vomiting in pediatric cancer.
LINK TO FULL TRANSCRIPT

319 Listeners

506 Listeners

40 Listeners

65 Listeners

766 Listeners

122 Listeners

2,237 Listeners

821 Listeners

188 Listeners

47 Listeners

31 Listeners

837 Listeners

59 Listeners

195 Listeners

46 Listeners